Nanotrol™ Therapeutics

Transforming CAR-T Therapy Safety Through AI-Powered Precision Medicine

90%
CRS Reduction
$500K
Cost Savings Per Patient
95%
AI Prediction Accuracy
$24B
Target Market by 2030

Our Mission

Transform CAR-T therapy from a high-risk, reactive treatment to a predictable, safe cure. We're building the world's first AI-powered platform that predicts and prevents cytokine release syndrome before it strikes, saving lives and reducing costs while preserving therapeutic efficacy.

🎯 SAVE LIVES • 💰 REDUCE COSTS • 🔮 PREDICT & PREVENT

The $3 Billion CRS Crisis

CAR-T's Life-Threatening Side Effect

The Human Cost

70-90%
Patients Develop CRS
5-15%
Mortality Rate
$1.2M
Treatment Cost
21 Days
Average ICU Stay

Current Solutions FAIL

Reactive Only: Wait for symptoms, then scramble to treat
No Prediction: Blind approach to life-threatening condition
High Mortality: 15% death rate from preventable complications
Massive Costs: $1.2M per patient with poor outcomes

The Human Impact

Families Devastated: Watching miracle cure become nightmare
Physicians Helpless: No tools to predict or prevent
Hospitals Overwhelmed: ICU resources strained
Industry Stalled: CRS fear limiting CAR-T adoption

Massive Market Opportunity

$24B CAR-T Market • 35% Annual Growth

$24B
Total Market by 2030
35%
Annual Growth Rate
50K+
Annual Patients
$2.1B
Our Target Market

Market Drivers

Expanding Indications: From blood cancers to solid tumors
Earlier Treatment Lines: Moving from last resort to first-line
Global Adoption: Worldwide CAR-T center expansion
Safety Imperative: Hospitals demanding CRS solutions

Critical Unmet Need

No Predictive Tools: $3B problem with no preventive solution
First-Mover Advantage: Capture market before competition
Regulatory Support: FDA fast-track potential for breakthrough
Payer Demand: Insurers desperate for cost reduction

Revolutionary Three-Pillar Platform

From Reactive to Proactive CRS Prevention

🤖

AI Prediction

95% accuracy using 47+ pre-treatment biomarkers to identify high-risk patients before CAR-T infusion

💊

Preventive Therapy

Nanosuspension salsalate targets multiple inflammatory pathways to prevent cytokine storm

🎯

Precision Delivery

Smart dosing based on individual risk profile with real-time monitoring and adjustment

90%
CRS Reduction
$500K
Savings Per Patient
0%
CAR-T Efficacy Impact
75%
ICU Cost Reduction

Game-Changing Value Proposition

PREDICT: 95% accuracy risk identification • PREVENT: 90% CRS reduction • PRESERVE: 100% CAR-T efficacy • PROFIT: $500K savings per patient

First Preventive CRS Solution

3-5 Year Head Start on Competition

Our Revolutionary Approach

Multi-Pathway Prevention: NF-κB, inflammasome, and TNF-α inhibition
AI-Powered Prediction: 47+ biomarkers, 95% sensitivity
Precision Dosing: Individualized therapy based on risk profile

Competition: Reactive Only

Tocilizumab: Wait-and-treat, $3K+ per dose, limited efficacy
Steroids: Broad immunosuppression, reduces CAR-T efficacy
Supportive Care: Manage symptoms, no prevention
$400
Our Cost per Course
$3,000+
Tocilizumab Cost
1st
Preventive Solution
3-5 Years
Competitive Head Start

Unassailable Competitive Position

First-mover advantage in prevention + AI prediction capabilities + cost advantages + proven safety profile = Market leadership for years to come

High-Margin Revenue Model

Four Scalable Revenue Streams

💊 Drug Sales (Primary)

85% Gross Margin
Direct sales to hospitals and CAR-T centers
$400 per patient course
Volume-based pricing tiers

🤖 AI Licensing

92% Gross Margin
SaaS model for prediction platform
$50 per patient prediction
Recurring subscription revenue

🧪 Diagnostic Tests

70% Gross Margin
Biomarker testing services
$200 per test panel
Laboratory partnership model

🤝 Strategic Partnerships

Variable Margin
Pharma licensing deals
Upfront + milestone + royalties
Technology transfer agreements

$2.5M
Year 1 Revenue
$35M
Year 3 Revenue
$180M
Year 5 Revenue
85%+
Average Gross Margin

Scalable, High-Margin Business

Multiple revenue streams reduce risk while maximizing value capture. Platform approach enables rapid scaling across indications and geographies.

World-Class Team

Proven Track Record of Execution

$1.7M
NIH SBIR Success
Several
Publications
15+
Years Experience
3
Patents

Leadership Team

Dr. Izhar Hasan, MD PhD
Founder & Chief Scientific Officer
NIH SBIR PI, Medical Director
World-Class Advisors
CAR-T clinical experts
AI/ML specialists, Regulatory veterans

Key Achievements

Proven Grant Success: $1.7M NIH SBIR Phase II award
IP Portfolio: US patent granted, international pending
Clinical Expertise: 15+ years urgent care medicine

Founder-Market Fit

Dr. Hasan uniquely combines clinical expertise, research credibility, and proven execution to lead Nanotrol™ to market success.

The Ask: $2M SAFE Note

24-Month Runway to Major Value Inflection

$2M
SAFE Note
$15M
Pre-Money Cap
24
Months Runway
3-5x
Expected Return

Use of Funds

$800K - Clinical Development (40%)
Phase I study completion, regulatory milestones
$600K - AI Platform (30%)
Algorithm refinement, validation studies
$400K - Team Building (20%)
Key hires: CMO, regulatory affairs
$200K - Operations (10%)
Legal, accounting, infrastructure

Key Milestones (24 Months)

Month 6: Phase I study initiation
First patient enrolled
Month 12: AI platform validation
Clinical decision support system
Month 18: Phase I safety data
Preliminary efficacy signals
Month 24: Series A readiness
$10-15M raise for Phase II

Founder's Biosketch - Izhar Hasan, MD PhD

Leadership Experience

Medical Director: Hackensack Meridian Urgent Care (2023-Present)
Chief Scientific Officer: Nanotrol™ Therapeutics, Inc. (2017-Present)
Medical Director: AFC Urgent Care Centers (2019-2023)
Assistant Professor: Rutgers and Hackensack School of Medicine (HSOM)

Education & Credentials

MD: Dow University of Health Sciences (1995)
PhD: Biomedical Informatics, Rutgers University (2013)
Board Certified: Family Medicine & Clinical Informatics
Licensed: New Jersey & California

Research Impact

Publications: Journals (Lancet, Cancer Research, Pediatric Neurosurgery)
15+ Presentations: International conferences on evidence-based medicine
Salsalate Research: Leading expert in NF-κB inhibition pathways
Global Teaching: Evidence-based medicine across multiple countries

Key Achievements

$1.7M NIH SBIR Phase II Grant: Principal Investigator for nanomedicine research
US Patent Granted: US11819488B2 with EU patent pending
Deputy Editor: Inflammopharmacology journal (Impact Factor: 5.8)
Clinical Excellence: 15+ years in urgent care and primary medicine

Regulatory Experience

Phase I Study Leadership: Oral micronized Salsalate clinical trial execution
Multiple INDs Submitted: Both Oral and IV formulations successfully filed
FDA Pathway Expertise: 505(b)(2) regulatory strategy development
Clinical Trial Design: Protocol development and regulatory compliance
$1.7M
NIH SBIR Grant
Several
Publications
15+
Years Experience
2
Board Certifications

Why Dr. Hasan is the Ideal Founder

Unique combination of clinical expertise in urgent care medicine, research credibility with NIH funding success, regulatory experience with patent prosecution, and academic leadership with teaching and editorial roles. Dr. Hasan deeply understands both the clinical problem and technological solution, with proven track record in nanomedicine development.

Financial Projections & Exit Strategy

$180M
Year 5 Revenue
25x
ROI Potential
$2-5B
Exit Valuation
2029
Target Exit

Revenue Projections

Year 1-2: $2.5M - $12M
Phase II completion, early partnerships
Year 3-4: $35M - $85M
Market launch, initial drug sales
Scale-up, AI licensing revenue
Year 5: $180M
Full market penetration

Value Inflection Points

Phase II Results (2027):
3-5x valuation increase
FDA Approval (2028):
5-10x valuation increase
Strategic Partnerships & Global Expansion:
Continuous value creation
10-25x exit multiple

Multiple Exit Pathways

Strategic Acquisition: Big Pharma acquisition for integrated CAR-T platform IPO Path: Public offering with platform expansion Licensing Deals: Technology licensing to multiple partners

1 / 10

Enter Password to Access Pitch Deck